7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” This study found that PRMT5 inhibitors showed potent anti-tumor activity in models of adenoid cystic carcinoma and that combining these inhibitors with lenvatinib may have additional growth-inhibitory effects.
2 citations
,
March 2020 in “Cns & Neurological Disorders-drug Targets” In this study, researchers analyzed lurasidone's risk profile for treating schizophrenia and bipolar depression, identifying unlisted adverse reactions like hypersexuality, restless leg syndrome, thrombocytopenia, and telogen effluvium, which show probable or possible correlations with the drug.
May 2024 in “Reactions weekly”
1 citations
,
May 2025 in “The Journal of Rheumatology” In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.
8 citations
,
June 2021 in “Frontiers in Medicine” This study reported that the combination of a 308-nm excimer lamp and 10% liquor carbonis detergens significantly improved scalp psoriasis symptoms compared to the excimer lamp alone, with more patients achieving 75% reduction in their Psoriasis Scalp Severity Index.
1 citations
,
March 1999 in “British journal of rheumatology” Adequate steroid treatment needed to limit bone loss in PMR patients.
This study provides insights into systemic lupus erythematosus patients' experiences with Anifrolumab, highlighting improvements in symptoms and health-related quality of life, despite ongoing daily life impacts.
April 2014 in “Investigative Ophthalmology & Visual Science” This report describes a case where a young woman developed Kerion Celsi, a fungal skin infection, potentially linked to the use of a tretinoin, minoxidil, and betamethasone valerate lotion.
January 2017 in “International journal of surgery and transplantation research” This study reviewed 647 facial enhancement surgeries using Covas-Lift, reporting reduced surgery time and fewer complications compared to traditional methods, with high patient satisfaction and minimal recovery issues observed.
20 citations
,
December 2016 in “Neurodegenerative disease management” This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.
70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.
This study reported that clascoterone cream reduced inflammatory and noninflammatory acne lesions in a trial with 1440 white males and non-pregnant females, showing it was well tolerated in these participants.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
May 2018 in “Journal of Clinical Oncology” This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.
September 2023 in “Journal of the American Academy of Dermatology” This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.
November 2025 in “Cochrane Database of Systematic Reviews” This study observed some differences in clinical outcomes when comparing CPA with spironolactone, flutamide, and finasteride, but no differences with other therapies, possibly due to small study size and non-standardized assessments; adverse effects could not be fully compared across treatments.
1 citations
,
September 2007 in “Neuromuscular disorders” This study suggests that long-term treatment with valproate, acetylcarnitine, folic acid, and vitamin B12 may benefit children with SMA types II and III by improving muscle strength and function without significant adverse effects.
October 2022 in “Journal of experimental and clinical medicine” This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” This study found a significant association between montelukast and neuropsychiatric adverse events such as suicidal ideation and depression, suggesting that the drug's interaction with specific genes may contribute to these effects.
April 2023 in “Dermatology practical & conceptual” This study concluded that lenalidomide significantly induces the proliferation and migration of melanocyte stem cells, enhancing their differentiation into functional melanocytes in a mouse model.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.
This study explored new molecular structures as potential COVID-19 treatments, identifying a compound called Hit15 that inhibited viral infection in lab settings and reduced inflammation markers in human neutrophils, suggesting further development is warranted.
2 citations
,
August 2017 in “Drug and therapeutics bulletin” This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.
January 2025 in “Biomedical Reports” This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.
March 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” This study concluded that teriflunomide has a consistent and manageable safety profile, with common mild-to-moderate adverse events and no new safety concerns identified over up to 12 years of treatment.
14 citations
,
January 2001 in “Current Treatment Options in Oncology” Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.
5 citations
,
March 2020 in “Thoracic Cancer” In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.